East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Phenoxybenzamine Hydrochloride Capsules USP, 10 mg. Aurobindo Pharma’s Phenoxybenzamine Hydrochloride Capsules, are an AB-rated generic equivalent to the reference listed drug (RLD), Dibenzyline® Capsules manufactured by Concordia Pharmaceuticals Inc.

Phenoxybenzamine Hydrochloride Capsules are indicated in:

• The treatment of pheochromocytoma, to control episodes of hypertension and sweating..